Related Experiment Video

Updated: Jun 17, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Oleuropein and hydroxytyrosol inhibit MCF-7 breast cancer cell proliferation interfering with ERK1/2 activation

Rosa Sirianni1, Adele Chimento, Arianna De Luca

  • 1Department of Pharmaco-Biology, University of Calabria, Arcavacata di Rende (CS), Italy.

Molecular Nutrition & Food Research
|December 17, 2009
PubMed

Insights

Hydroxytyrosol (HT) and oleuropein (OL) from olive oil inhibit breast cancer cell proliferation. These polyphenols block estrogen-dependent signaling pathways, suggesting a potential chemo-preventive role against tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Nutritional Science

Background:

  • Estradiol (E2) stimulates growth in many breast tumors via gene expression and signal transduction.
  • Natural polyphenols with estrogen-like structures can impede tumor cell proliferation.
  • Extra-virgin olive oil contains hydroxytyrosol (HT) and oleuropein (OL), potential anti-cancer agents.

Purpose of the Study:

  • To investigate the effects of HT and OL on breast cancer cell proliferation.
  • To determine if HT and OL interfere with estradiol (E2)-induced molecular mechanisms.
  • To explore the chemo-preventive potential of HT and OL in breast cancer.

Main Methods:

  • Assessing the impact of HT and OL on MCF-7 breast cancer cell proliferation.
  • Utilizing luciferase gene reporter assays with estrogen-responsive elements to evaluate ERalpha activity.
  • Measuring ERalpha expression levels after HT or OL treatment.
  • Analyzing the effect of HT and OL on E2-dependent activation of extracellular regulated kinase1/2 (ERK1/2).

Main Results:

  • Both HT and OL significantly inhibited the proliferation of MCF-7 breast cancer cells.
  • HT and OL did not affect ERalpha-mediated gene expression.
  • HT and OL demonstrated a clear inhibition of E2-dependent activation of mitogen-activated protein kinase (MAPK) pathway, specifically ERK1/2.
  • These findings suggest a novel mechanism of action for HT and OL in breast cancer.

Conclusions:

  • Hydroxytyrosol (HT) and oleuropein (OL) exhibit anti-proliferative effects on breast cancer cells.
  • The chemo-preventive role of HT and OL may stem from their ability to inhibit rapid estrogen-dependent signaling pathways.
  • These findings highlight the potential of dietary polyphenols in breast cancer prevention and treatment.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...